{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:10:27Z","timestamp":1790856627781,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T00:00:00Z","timestamp":1095984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> CD4<jats:sup>+<\/jats:sup>CD25<jats:sup>+<\/jats:sup> T cells are an important population that plays a crucial role in the maintenance of peripheral self\u2010tolerance. Recently, it was shown that the elimination of these cells by <jats:italic>in vivo<\/jats:italic> administration of anti\u2010CD25 monoclonal antibody (mAb) caused the regression of highly immunogenic tumors in syngeneic mice. In this study, we examined whether B16F10 melanoma cells regressed with the elimination of CD25<jats:sup>+<\/jats:sup> regulatory T cells. We found the melanoma cells were not affected at all by <jats:italic>in vivo<\/jats:italic> anti\u2010CD25 mAb administration alone but tumor rejection resulted in all mice when the administration was combined with IL\u201012 gene transfer to tumor cells. <jats:italic>In vivo<\/jats:italic>, depletion of natural killer (NK) cells or CD8<jats:sup>+<\/jats:sup> T cells cancelled the tumor rejection. NK\u2010cell depletion allowed IL\u201012\u2010transfected B16F10 melanoma (B16\/IL\u201012) to grow from an early stage and resulted in a more rapid tumor growth of B16\/IL\u201012 than that in mice without administration of anti\u2010CD25 mAb. On the other hand, CD8<jats:sup>+<\/jats:sup> T\u2010cell depletion did not affect the tumor growth in the early phase but allowed B16\/IL\u201012 to grow in rather a late phase and resulted in almost the same degree of tumor growth as in mice without administration of anti\u2010CD25 mAb. In a previous study, we showed that the elimination of CD4<jats:sup>+<\/jats:sup> T cells enhanced the antitumor effect of B16\/IL\u201012 and induced vitiligo\u2010like coat color alteration. Therefore, we also examined the frequency of the change to a vitiligo\u2010like coat color in mice showing tumor rejection caused by CD25<jats:sup>+<\/jats:sup> T\u2010cell elimination to compare with the mechanism enhancing the antitumor effects by cell elimination. The elimination of CD25<jats:sup>+<\/jats:sup> T cells did not induce vitiligo\u2010like coat color changes, though that of CD4<jats:sup>+<\/jats:sup> T cells induced the change in 60% of mice. Furthermore, we confirmed that elimination of CD25<jats:sup>+<\/jats:sup> T cells did not affect the T\u2010helper (Th) 1\/Th2 cytokine profile, while that of CD4<jats:sup>+<\/jats:sup>T cells abrogated the Th2 cytokines (IL\u20104 and IL\u201010) and resulted in a Th1\u2010dominant cytokine profile in the tumor\u2010draining lymph nodes (TDLNs) of B16\/IL\u201012\u2010bearing mice. These results indicate that <jats:italic>in vivo<\/jats:italic> depletion of CD25<jats:sup>+<\/jats:sup> regulatory T cells is a potent useful adjuvant in immunotherapy of B16F10 melanoma, when combined with IL\u201012 gene transfer and that the enhancement of the antitumor effect by CD25<jats:sup>+<\/jats:sup> T\u2010cell depletion is mediated through CD8<jats:sup>+<\/jats:sup> T cells and may differ from the enhancing mechanism caused by CD4<jats:sup>+<\/jats:sup> T\u2010cell depletion.<\/jats:p>","DOI":"10.1111\/j.0906-6705.2004.00198.x","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T13:18:10Z","timestamp":1096031890000},"page":"613-620","source":"Crossref","is-referenced-by-count":62,"title":["<i>In vivo<\/i> elimination of CD25<sup>+<\/sup> regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin\u201012 gene transfer"],"prefix":"10.1111","volume":"13","author":[{"given":"Hiroshi","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Oniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Nishigori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Ichihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,9,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/newbio242148a0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357900009031825"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00156.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80856-9"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self\u2010tolerance maintained by activated T cells expressing IL\u20102 receptor \u03b1\u2010chains (CD25). Breakdown a single mechanism of self\u2010tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi S","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260730"},{"key":"e_1_2_6_8_2","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti\u2010CD25 (interleukin\u20102 receptor \u03b1) monoclonal antibody","volume":"59","author":"Onizuka S","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.3.2.280"},{"key":"e_1_2_6_10_2","first-page":"33","volume-title":"Molecular cloning.","author":"Sambrook J","year":"1982"},{"key":"e_1_2_6_11_2","first-page":"327","article-title":"Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter","volume":"1","author":"Southern P J","year":"1982","journal-title":"J Mol Appl Genet"},{"key":"e_1_2_6_12_2","first-page":"1","volume-title":"Current Protocols in Immunology","author":"Gately M K","year":"1992"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(87)90021-2"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.17.6808"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909309018881"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V84.12.4008.bloodjournal84124008","article-title":"Interleukin\u201012: a cytokine produced by antigen\u2010presenting cells with immunoregulatory functions in generation of T\u2010helper cells type 1 and cytotoxic lymphocytes","volume":"84","author":"Trinchieri G","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.4.1223"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.908a"},{"key":"e_1_2_6_20_2","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins M B","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_21_2","first-page":"2541","article-title":"Effects of single\u2010dose interleukin\u201012 exposure on interleukin\u201012\u2010associated toxicity and interferon\u2010gamma production","volume":"90","author":"Leonard J P","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_22_2","first-page":"9","article-title":"Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer","volume":"5","author":"Robertson M J","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_23_2","first-page":"75","article-title":"Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma","volume":"4","author":"Bajetta E","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_24_2","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin\u201012 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer R J","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300891"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0601"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.10.762"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018850"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.110306.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001090000165"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303403322124765"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.12.1969"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2001.1820105.x"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0906-6705.2004.00198.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0906-6705.2004.00198.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T01:43:33Z","timestamp":1696988613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0906-6705.2004.00198.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,24]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.0906-6705.2004.00198.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0906-6705.2004.00198.x","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,24]]}}}